6100 Merriweather Dr., Suite 600
Columbia, MD 21044
410-884-2900

PROTOCOL APPROVAL WITH MODIFICATIONS

DATE: 3 Nov 2021

TO: Kathie Thomas

PROTOCOL: American Heart Association-TX - 1.0, Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation (CHANGE AFib). (Pro00057635)

APPROVAL DATE: 29 Oct 2021

EXPIRATION DATE: 29 Oct 2022

IRB APPROVED DOCUMENTATION:

Protocol Version(s):

- Protocol Version 1.0 (Not Dated)

Consent Template(s):

- Informed Consent Form (Advarra IRB Approved Version 29 Oct 2021)

Product Information:

- Investigator's Brochure for SR33589B (Edition: 12, Issue Date: 19 October 2011)
- Prescribing Information for MULTAQ (dronedarone) Tablets (Revised: 7/2009)
- Safety Data Sheet for DRONEDARONE HYDROCHLORIDE (Version:3.0, Revision Date: 26.08.2020)

Recruitment Material:

- Flyer, poster, or bulletin board, "Newly diagnosed atrial fibrillation can be overwhelming. Learn about the CHANGE AFib trial that may help patients with newly-detected AFib." (Not Dated)
- Flyer, poster, or bulletin board, "CHANGE AFib: A Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation" (Not Dated)

Other Material:

- Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire (Version 1.0)
- Questionnaire, Mayo AF-Specific Symptom Inventory (MAFSI) (Not Dated)
- MEDICAL RECORDS RELEASE FORM (V2)
- Physician Pocket Card (Not Dated)
- Change AFib GWTG-AFib Hospital CRF (Dated 9.30.21)

- CHANGE_AFib 3-9 month Follow-up Form (Dated 10.14.21)
- CHANGE_AFib 12 month Follow-up Form (Dated 10.14.21)

The IRB approved the above referenced protocol with the modifications listed below on 29 Oct 2021:

- **Modifications to the Informed Consent Form**
- **Modifications to the Study to Submit a revised protocol or protocol administrative letter (to be distributed to the site(s)) that encompass the following:**

  1. The protocol is absent of contraception requirements for male participants in the study protocol. The board requires male contraception during the study and for 7 days after the last dose of study drug to prevent pregnancy in female partners. This timeline was chosen based on the half life of the study drug.

If you wish to appeal the IRB's determinations and/or imposed modifications, you may follow the procedures outlined below:

1. Submit supporting documentation that addresses the IRB's concerns.
2. Provide a written justification for relief of any IRB imposed condition.

On 1 Nov 2021, the IRB reviewed and approved the Protocol Version 1.0 that met the requirement of the IRB for the above referenced Modification to the study.

Use of eConsent is Approved.

Based on the confirmations provided to the IRB, it is expected that:

1. The eConsent(s) will include the complete and exact contents of the most current, IRB approved study consent(s).
2. The eConsent process includes obtaining signature(s) in compliance with applicable law and a method to confirm the identity of the signer(s).
3. The stored eConsent(s) identify the signers and date (time, if applicable) of signing; signed eConsent(s) are stored with appropriate access, and all versions are retrievable.
4. The signers must review all consent contents prior to signing the eConsent (i.e., there is no function available to skip directly to the signature field(s)).
5. All subject-facing materials used during the eConsent process (e.g., web-linked materials, graphics, videos, glossary, etc.) will be submitted for IRB approval.
6. If CIRBI eConsent Attestation responses change, an eConsent Modification will be submitted to the IRB for review. Note: An eConsent Modification is not required when revisions are only to the IRB approved study consent document(s).

Individual sites with site-specific changes to the sponsor-level ICF must submit an Attestation Letter stating that their eConsent is a complete and exact copy of the IRB approved ICF document for their site, OR describing the elements that are different. Sites with site-specific changes to the sponsor-level ICF must also submit eConsent screenshots, as well as any eConsent content that is different from the IRB approved sponsor eConsent documents, as described in the Attestation Letter (i.e., Video Storyboard, Glossary of Terms, links). Note: Individual sites that do not have site-specific changes to the sponsor-level ICF do not need to submit their own eConsent documents.

The above referenced recruitment/subject material is available on your Advarra CIRBI Platform workspace under the "IRB Issued Documents" tab.

Please Note: This approval notice is for the IRB approval of the protocol only. The Principal Investigator for each site must complete a separate site submission to receive an IRB Approval notice allowing them to conduct the study.

Subpart D Determination – Newborn follow-up
21 CFR 50.51 / 45 CFR 46.404
This protocol plans to collect data regarding a newborn child born to a female subject on the clinical trial. The Board performed a Subpart D analysis and determined that this follow-up portion of the study presents no more than minimal risk (21 CFR 50.51/45 CFR 46.404). The Board requires that one parent or the legal guardian provide permission for the minor to participate in the research. Assent from the minor subject is not required due to infancy.

Subpart B Determination – Pregnancy follow-up
45 CFR 46.204
This protocol plans to collect data on the pregnancy of female subjects on the clinical trial and the Board determined that the research meets requirements under Subpart B. The Board determined that this follow-up portion of the research presents no more than minimal risk, there is no prospect of direct benefit to the woman or the fetus, and the purpose of the research is the development of important biomedical knowledge which cannot be obtained by any other means. The Board requires that consent to participate in this research study be obtained from the pregnant woman.

If the study is expected to last beyond the approval period, you must request and receive re-approval prior to the expiration date noted above. A report to the Board on the status of this study is due prior to the expiration date or at the time the study closes, whichever is earlier. It is recommended that you submit status reports at least 4 weeks prior to your expiration date to avoid any additional fees or lapses in approval.

Approved investigators and sites are required to submit to Advarra for review, and await a response prior to implementing: any amendments or changes in the protocol; informed consents; advertisements or recruitment materials ("study-related materials"); investigators; or sites (primary and additional).

Approved investigators and sites are required to notify Advarra of the following reportable events, including, but not limited to: unanticipated problems involving risks to subjects or others; unanticipated adverse device effects; protocol violations that may affect the subjects' rights, safety, or well-being and/or the completeness, accuracy and reliability of the study data; subject death; suspension of enrollment; or termination of the study.

Please review the IRB Handbook located in the "Reference Materials" section of the Advarra CIRBI™ Platform (www.cirbi.net). A copy of the most recent IRB roster is also available.

Thank you for selecting Advarra IRB to provide oversight for your research project.